



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Taki, AC;Wang, T;Nguyen, NN;Ang, CS;Leeming, MG;Nie, S;Byrne, JJ;Young, ND;Zheng, Y;Ma, G;Korhonen, PK;Koehler, AV;Williamson, NA;Hofmann, A;Chang, BCH;Häberli, C;Keiser, J;Jabbar, A;Sleeb, BE;Gasser, RB

Title:

Thermal proteome profiling reveals Haemonchus orphan protein HCO\_011565 as a target of the nematocidal small molecule UMW-868

Date:

2022-10-14

Citation:

Taki, A. C., Wang, T., Nguyen, N. N., Ang, C. S., Leeming, M. G., Nie, S., Byrne, J. J., Young, N. D., Zheng, Y., Ma, G., Korhonen, P. K., Koehler, A. V., Williamson, N. A., Hofmann, A., Chang, B. C. H., Häberli, C., Keiser, J., Jabbar, A., Sleeb, B. E. & Gasser, R. B. (2022). Thermal proteome profiling reveals Haemonchus orphan protein HCO\_011565 as a target of the nematocidal small molecule UMW-868. *Frontiers in Pharmacology*, 13, <https://doi.org/10.3389/fphar.2022.1014804>.

Persistent Link:

<https://hdl.handle.net/11343/325337>

License:

CC BY



## OPEN ACCESS

## EDITED BY

Heike Wulff,  
University of California, Davis,  
United States

## REVIEWED BY

Ziaurrehman Tanoli,  
University of Helsinki, Finland  
Paul M. Selzer,  
Boehringer Ingelheim Vetmedica  
GmbH, Germany

## \*CORRESPONDENCE

Brad E. Sleebs,  
sleebs@wehi.edu.au  
Robin B. Gasser,  
robinbg@unimelb.edu.au

<sup>†</sup>These authors have contributed equally  
to this work

## SPECIALTY SECTION

This article was submitted to  
Experimental Pharmacology and Drug  
Discovery,  
a section of the journal  
Frontiers in Pharmacology

RECEIVED 11 August 2022

ACCEPTED 20 September 2022

PUBLISHED 14 October 2022

## CITATION

Taki AC, Wang T, Nguyen NN, Ang C-S,  
Leeming MG, Nie S, Byrne JJ,  
Young ND, Zheng Y, Ma G,  
Korhonen PK, Koehler AV,  
Williamson NA, Hofmann A, Chang BCH,  
Häberli C, Keiser J, Jabbar A, Sleebs BE  
and Gasser RB (2022), Thermal  
proteome profiling reveals  
Haemonchus orphan protein  
HCO\_011565 as a target of the  
nematocidal small molecule UMW-868.  
*Front. Pharmacol.* 13:1014804.  
doi: 10.3389/fphar.2022.1014804

## COPYRIGHT

© 2022 Taki, Wang, Nguyen, Ang,  
Leeming, Nie, Byrne, Young, Zheng, Ma,  
Korhonen, Koehler, Williamson,  
Hofmann, Chang, Häberli, Keiser,  
Jabbar, Sleebs and Gasser. This is an  
open-access article distributed under the  
terms of the [Creative Commons  
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,  
distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Thermal proteome profiling reveals *Haemonchus* orphan protein HCO\_011565 as a target of the nematocidal small molecule UMW-868

Aya C. Taki<sup>1†</sup>, Tao Wang<sup>1†</sup>, Nghi N. Nguyen<sup>2</sup>, Ching-Seng Ang<sup>3</sup>,  
Michael G. Leeming<sup>3</sup>, Shuai Nie<sup>3</sup>, Joseph J. Byrne<sup>1</sup>,  
Neil D. Young<sup>1</sup>, Yuanting Zheng<sup>1</sup>, Guangxu Ma<sup>1,4</sup>,  
Pasi K. Korhonen<sup>1</sup>, Anson V. Koehler<sup>1</sup>, Nicholas A. Williamson<sup>3</sup>,  
Andreas Hofmann<sup>1</sup>, Bill C. H. Chang<sup>1</sup>, Cécile Häberli<sup>5,6</sup>,  
Jennifer Keiser<sup>5,6</sup>, Abdul Jabbar<sup>1</sup>, Brad E. Sleebs<sup>1,2,7\*</sup> and  
Robin B. Gasser<sup>1\*</sup>

<sup>1</sup>Department of Veterinary Biosciences, Faculty of Veterinary and Agricultural Sciences, Melbourne Veterinary School, The University of Melbourne, Parkville, VIC, Australia, <sup>2</sup>Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, <sup>3</sup>Melbourne Mass Spectrometry and Proteomics Facility, The Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC, Australia, <sup>4</sup>Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, College of Animal Sciences, Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou, Zhejiang, China, <sup>5</sup>Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland, <sup>6</sup>University of Basel, Basel, Switzerland, <sup>7</sup>Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia

Parasitic roundworms (nematodes) cause destructive diseases, and immense suffering in humans and other animals around the world. The control of these parasites relies heavily on anthelmintic therapy, but treatment failures and resistance to these drugs are widespread. As efforts to develop vaccines against parasitic nematodes have been largely unsuccessful, there is an increased focus on discovering new anthelmintic entities to combat drug resistant worms. Here, we employed thermal proteome profiling (TPP) to explore hit pharmacology and to support optimisation of a hit compound (UMW-868), identified in a high-throughput whole-worm, phenotypic screen. Using advanced structural prediction and docking tools, we inferred an entirely novel, parasite-specific target (HCO\_011565) of this anthelmintic small molecule in the highly pathogenic, blood-feeding barber's pole worm, and in other socioeconomically important parasitic nematodes. The "hit-to-target" workflow constructed here provides a unique prospect of accelerating the simultaneous discovery of novel anthelmintics and associated parasite-specific targets.

## KEYWORDS

thermal proteome profiling, anthelmintic discovery, target identification, structure modelling, in silico docking

## 1 Introduction

Parasitic diseases of humans and other animals represent a major socioeconomic burden worldwide. In humans, parasitic worms (= helminths) that cause neglected tropical diseases (NTDs) affect ~1 billion people, equating to a burden of two million disability-adjusted life years (DALYs) (Loukas et al., 2021). In animals, although challenging to quantitate, the disease impact of parasitic helminths is substantial (Pedersen and Fenton, 2015; Charlier et al., 2020; Selzer and Epe, 2020), and some species are also transmissible to humans (i.e., zoonotic) (McCarthy and Moore, 2000; Gordon et al., 2016). The control of these diseases (= helminthiasis) relies on diagnosis, treatment and management strategies, and anthelmintic treatment is usually a central component of control campaigns, as vaccines are not available for the majority of parasites, including hookworms (*Ancylostoma* and *Necator*), threadworms (*Strongyloides*) and whipworms (*Trichuris*) (Jex et al., 2011). Anthelmintic treatments are not always highly efficacious/effective, and the reliance on them, particularly if they are used excessively in an uncontrolled (suppressive) manner, has led to the emergence and spread of anthelmintic resistance in parasitic worms (Kotze and Prichard, 2016; Hodgkinson et al., 2019), particularly those of animals. Although the resistance status of worms of humans to available compounds is somewhat unclear (Prichard, 2005; Keiser and Utzinger, 2008; Vercruyse et al., 2011), this is not the case for worms of important production animals (e.g., sheep, goats and cattle), where such resistance is widespread and essentially worldwide.

As developing vaccines against most helminths (particularly nematodes) has been extremely challenging, the focus has been on the discovery and development of new, highly efficacious anthelmintics, intended to circumvent these resistance problems. However, the last new compounds (derquantel and monepantel) were released commercially in 2010, and since that time, no new chemotypes have entered clinical trials. To support discovery efforts, a number of academic teams around the world have contributed to early phase work to identify new anthelmintic entities for subsequent optimisation and development in public-private partnerships (PPPs) (Ramamoorthi et al., 2014; Partridge et al., 2018; Pasche et al., 2018; Taylor et al., 2019; Weber et al., 2019; Clare et al., 2019; HELP (Helminth Elimination Platform), 2019; Taki et al., 2021a).

Our focus has been on screening a range of curated compound libraries using phenotypic assays for the parasitic nematode *Haemonchus contortus*—called the barber's pole worm (Jiao et al., 2020; Herath et al., 2021; Herath et al., 2022). We employ this worm species, because 1) it is a highly significant, pathogenic nematode with a high reproductive index, and can be readily maintained in a laboratory environment; 2) it represents one of the largest groups (clade V) of socioeconomically relevant nematodes of animals, including a range of species parasitic in humans; 3) it is relatively closely related to *Caenorhabditis*


*elegans* (also clade V)—a free-living nematode—which is one of the best understood multicellular organisms (Holden-Dye and Walker, 2014; Hahnel et al., 2020) and for which extensive biological, biochemical, molecular, genetic and genomic resources exist (Harris et al., 2019; Davis et al., 2022); and 4) it now assumes 'model organism' status (Doyle et al., 2020) due to the availability of extensive genomic, transcriptomic, proteomic and lipidomic data sets and resources for this parasitic nematode (Laing et al., 2013; Schwarz et al., 2013; Gasser et al., 2016; Ma et al., 2018; Wang et al., 2018; Wang et al., 2019a; Wang et al., 2019b; Ma et al., 2020a; Wang et al., 2020a; Ma et al., 2020b; Wang et al., 2020b; Doyle et al., 2020; Wang et al., 2021; Wang and Gasser, 2021). Thus, *H. contortus* is exceptionally well suited as a biological tool for anthelmintic discovery.

In recent work, we established a high-throughput whole-organism, phenotypic assay for the screening of relatively large libraries of tens to hundreds of thousands of compounds, the subsequent evaluation of active compounds and structure-activity relationship (SAR) studies to strive toward the optimisation of the activity and potency of analogs (Taki et al., 2021a; Taki et al., 2021b; Shanley et al., 2022). A challenge has been target-deconvolution to support optimisation efforts. Published evidence (Savitski et al., 2014; Perrin et al., 2020; Mateus et al., 2022) demonstrates clearly the exquisite capacity of thermal proteome profiling (TPP) to define or infer target molecules in projects with a biomedical focus (e.g., cancers), but this approach has not yet been utilised to define anthelmintic targets. This context provides the very exciting prospect of being able to rapidly provide evidence of drug-target interactions. Here, we used a high-throughput whole-organism, phenotypic screen of a well-curated compound library to identify new starting points for optimisation against *H. contortus*, and employed TPP to better understand hit pharmacology and support optimisation.

## 2 Results

### 2.1 High throughput screen and potency evaluation identify a drug-like compound (UMW-868) with activity against *H. contortus*

We screened the 14,400 compounds from the Hitfinder Collection from Maybridge (Figure 1A) on exsheathed third-stage larvae (xL3s) of *H. contortus* at a concentration of 20  $\mu$ M. At 90 h, we identified 36 compounds that reduced xL3 motility by  $\geq 70\%$ , equating to an overall "hit rate" of 0.25% (Figure 1A; Supplementary Table S1). At 168 h, 21 of these 36 compounds induced abnormal (non-wildtype) larval phenotypes, detectable with reference to the wildtype (negative control). Next, we selected 11 of the 36 hits (Figure 1A) exhibiting favourable, drug-like features for further evaluations. Dose-response



evaluations of motility reduction on xL3s (90 h) and larval development inhibition (168 h) identified 6 of the 11 compounds (Figure 1B) with strong activity with  $\text{IC}_{50}$  values between 2.6  $\mu\text{M}$  and 11.2  $\mu\text{M}$ . Of these six compounds, UMW-868 was one of the most potent compounds against xL3s of *H. contortus*, has a drug-like structure similar to that of tioxazafen—described as being a “broad-spectrum” nematocide (South and Wilson, 2016) and was, thus,

considered as suitable for further assessment (Figure 1C). UMW-868 showed  $\text{IC}_{50}$  values of 5.6  $\mu\text{M}$  (motility) and 5.8  $\mu\text{M}$  (development), with an ability to induce abnormal (curved or evisceration) phenotypes in affected xL3s (Figure 1C and Supplementary Figure S1). Subsequently, we assessed the effect of UMW-868 *in vitro* on adult females of *H. contortus* collected directly from the abomasum of a sheep with a patent (30 days) infection. The motility of UMW-868-




FIGURE 2

Bioassay characterisation of compound UMW-868. (A) Structures of UMW-868 (active) and its analog A-3155 (inactive). (B) Dose-response assessment of the *in vitro* lethality of UMW-868 for inducing cell death in exsheathed third-stage larvae (xL3s) of *Haemonchus contortus* over 90 h, with reference to xL3s exposed to control compounds, M-666 (lethal) and A-3155 (non-lethal). (C) Dead cells detected microscopically of UMW-868-treated xL3s stained with Sytox Green nucleic acid stain, observed under 40-times magnification, with reference to xL3s exposed to A-3155 (non-lethal) and no-compound control (containing 0.2% (v/v) DMSO). (D) Cellular and mitochondrial toxicities of UMW-868 and two non-toxic compounds, monepantel (MON) and moxidectin (MOX) on HepG2 human hepatoma cells, using control compounds (doxorubicin and M-666) for respective toxicities.

treated adult females reduced by 37.5% after 5 h of exposure, and by 66.7% after 24 h; the latter reduction was comparable to the moxidectin positive-control (Figure 1C and Supplementary Table S2). The subsequent *in vitro* activity/potency assessment of UMW-868 on the hatching of *H. contortus* eggs revealed an  $\text{IC}_{50}$  value of 6.2  $\mu\text{M}$  (Figure 1C). Based on the results from potency assessments, UMW-868 was selected for further investigation (Figure 1D).

## 2.2 UMW-868 causes major cell death in *H. contortus*, but no cytotoxicity or mitotoxicity in mammalian hepatic cells *in vitro*

Initially, we measured cell death in UMW-868-treated xL3s of *H. contortus*. After 90 h of exposure, cell death was detected in the UMW-868-treated xL3s (>5  $\mu\text{M}$ ), while xL3s treated with an


inactive analog (A-3155) remained viable (Figure 2A). UMW-868 killed 100% of treated xL3s at 50  $\mu\text{M}$ , with an  $\text{IC}_{50}$  value of 34.8  $\mu\text{M}$  (Figure 2B). After 168 h of exposure to UMW-868, dead cells could be seen throughout the larvae (Figure 2C), while no dead cells were detected in xL3s exposed to A-3155 or DMSO (Figure 2C). Next, we tested UMW-868 on HepG2 cells and mitochondria for toxicity; UMW-868 did not display any appreciable cytotoxicity or mitotoxicity at concentrations of up to 100  $\mu\text{M}$  (Figure 2D).


## 2.3 Activity of UMW-868 on other nematodes *in vitro* and *in vivo*

We investigated the activity of UMW-868 on other species of parasitic nematodes of humans and animals, and on the free-living nematode *Caenorhabditis elegans* (Supplementary Table S3). After 72 h of exposure at 10  $\mu\text{M}$  *in vitro*, UMW-868 killed ~100% of third-stage larvae (L3s) and adults of *Ancylostoma ceylanicum* and of L3s of *Strongyloides ratti*. At 1  $\mu\text{M}$ , UMW-868 killed 50% of *A. ceylanicum* adults and 30% of *S. ratti* L3s, but did not affect *A. ceylanicum* larvae at this concentration. UMW-868 was also partially effective at killing other species of nematodes including *Necator americanus* (13%), *Heligmosomoides polygyrus* (13%) and *Trichuris muris* (24%). After 72 h of exposure at 10  $\mu\text{M}$  *in vitro*, UMW-868 reduced the motility of *C. elegans* by 53.5% at 40 h, and had an  $\text{IC}_{50}$  value of 9.9  $\mu\text{M}$ . Subsequently, we assessed the activity of UMW-868 against *He. polygyrus* in mice and *A. ceylanicum* in hamsters (Supplementary Table S4). Using a single oral dose of 100 or 200 mg/kg body weight, UMW-868 reduced the intensities of *A. ceylanicum* and *He. polygyrus* infections by 48% and 47%, respectively. Throughout these experiments, there was neither evidence of acute toxicity in animals, nor was there evidence of pathological changes on skin or in internal organs (liver, lung, spleen and gastrointestinal tract) upon post-mortem examination of animals.

## 2.4 Evidence that orphan protein HCO\_011565 is a target of UMW-868

Given the clear evidence that UMW-868 has anthelmintic activity and no cell or mitochondrial toxicity in mammalian hepatic cells, we aimed to identify this compound's target/s. Using thermal proteome profiling (TPP), we identified and quantified a total of 3,678 *H. contortus* proteins (Figure 3A; Supplementary Table S5), a subset of the somatic proteome defined recently for this parasite (Wang et al., 2019b). The full list of quantified proteins at each temperature point along the






gradient (37–67°C) is given in [Supplementary Table S4](#). Both heatmap and box plot analyses revealed marked decreases in relative protein abundances for UMW-868- or PBS-treated *H. contortus* xL3-homogenate samples with increasing temperature ([Figures 3B,C](#)). After assessing thermal profiles of quantified proteins by nonparametric analysis of response curves (NPARC), and fitting nonparametric models to the temperature profile data under the null and alternative hypotheses ([Childs et al., 2019](#)), we yielded 2,591 distinct melting curve profiles. Following filtering, we identified 55 proteins whose thermostability and abundance were altered in the presence of UMW-868. Of these 55 proteins, two uncharacterised (unknown or orphan) proteins (encoded by genes HCO\_011565 and HCO\_014287, respectively) exhibited the highest, statistically significant thermostability in the presence of UMW-868 with reference to the phosphate-buffered saline (PBS) control ([Figure 3D](#)), suggesting that they are targets for UMW-868.

In the absence of crystal structures for these two proteins, we predicted their conformations using a high-performance

algorithm, AlphaFold2 ([Jumper et al., 2021](#)) (cf. Materials and Methods; [Section 4](#)). Although AlphaFold could not predict a confident structure for HCO\_014287, the model for HCO\_011565, containing one transmembrane domain at the C-terminus, was well-supported (confidence score of 87.3; [Figure 4A](#)). Subsequently, we explored transcription/expression levels for these two molecules. For HCO\_011565, we showed a constitutive transcription in all key developmental stages of *H. contortus* and a high expression in the egg, L3, L4 (fourth larval) and adult stages. For HCO\_014287, we recorded moderate to high transcription only in the L2 (second larval) and L3 stages, but limited or no expression in other developmental stages ([Figure 4B](#)). Based on these findings, HCO\_011565 was selected for further investigation.

*In silico* docking experiments indicated that UMW-868 docked into a pocket (cavity size: 384 Å<sup>3</sup>) of HCO\_011565 with a Vina score of -6.9 ([Figure 4C](#)). Given that UMW-868 was shown to have distinct levels (13–100%)





of anthelmintic activities *in vitro* or *in vivo* against distinct developmental stages of nematodes other than *H. contortus*, including *A. ceylanicum*, *C. elegans*, *He. polygyrus*, *N. americanus* and *S. ratti*, we studied the primary protein sequences of HCO\_011565 orthologs in these nematodes, modelled individual proteins and then compared the structural models (Figure 4D). Despite significant/marked amino acid differences (19.9%–67.7%) among primary sequences, respective predicted structures were relatively conserved (confidence scores of 85.4–87.3), upon pairwise comparison (Supplementary Figure S2). UMW-868 was also predicted to dock into a pocket in the *C. elegans* ortholog (Y92H12BR.3a) of HCO\_011565, with a Vina score of  $-6.3$  (Supplementary Table S6). However, this was not the case for HCO\_011565 orthologs of the other nematode species studied, suggesting that UMW-868 has one or more alternative targets in these worms. Although the differences in binding modes predicted here might partially explain the variable activities/potencies of UMW-868 recorded for individual nematode species studied, other factors, such as developmental stage, presence/absence of a cuticular sheath (i.e., L3s *versus* other stages) and ability to ingest/uptake and absorb/transport the compound; nature and extent target protein expression in a particular developmental stage; and/or type of assay employed (i.e., *in vitro* or *in vivo*), also need careful consideration.

## 2.5 Medicinal chemistry leads to enhanced potency in *H. contortus*

Given UMW-868's promising activity and structure as a nematocidal candidate, we focused on modifying its chemistry (Figure 5) to attempt to enhance potency and further assessed cyto- and mito-toxicity on HepG2 cells (Table 1). In the “southern region” ( $R^1$ ) of UMW-868, the substitution of aryl ring with thiophene did not alter potency to reduce xL3-motility (A-3126;  $\text{IC}_{50}$  12.1  $\mu\text{M}$ ), as expected. However, the potency increased with the addition of 4-methyl to aryl group (A-3136;  $\text{IC}_{50}$  4.8  $\mu\text{M}$ ), and enhanced further with 4-trifluoromethyl substitution (A-6501;  $\text{IC}_{50}$  1.6  $\mu\text{M}$ ). In the “northern region” ( $R^2$ ), the replacement of the *n*-propyl substituent with an ethoxy group increased potency (A-3134;  $\text{IC}_{50}$  7.8  $\mu\text{M}$ ), and was enhanced further through the introduction of a 4-difluoromethoxy group (A-4340;  $\text{IC}_{50}$  4.0  $\mu\text{M}$ ). In accordance with the results for xL3-motility reduction, some of these modified analogs (i.e., A-3136, A-6318, A-6501 and A-4340) had enhanced inhibitory activity/potency on larval development (Table 1). Interestingly, the related nematocidal compound—tioxazafen (A-8417) (South and Wilson, 2016)—was not active against xL3s, and did not inhibit larval development or egg hatching ( $\text{IC}_{50} > 50 \mu\text{M}$ ; see Table 1). Finally, the combination of the best south ( $R^1$ ) and north ( $R^2$ ) modifications, an analog with 4-trifluoromethyl substituent on the

**TABLE 1** Potencies ( $IC_{50}$  in  $\mu M$ ) of UMW-868 analogs with iterations of the aryl ( $R^1$ ) and *n*-propyl ( $R^2$ ) substituents of UMW-868 and tioxazafen on the motility of exsheathed third-stage larvae (xL3s) and development of fourth-stage larvae (L4s) at 168 h, and the hatching of eggs of *Haemonchus contortus* at 48 h; and results from an assessment of the toxicity of individual compounds on human hepatoma (HepG2) cells ( $CC_{50}$ ) and the mitochondria ( $MC_{50}$ ) of these cells.

Compound	$R^1$	$R^2$	<i>H. contortus</i>			HepG2 (human hepatoma) cells	
			xL3 motility reduction ( $IC_{50}$ in $\mu M$ )	L4 development inhibition ( $IC_{50}$ in $\mu M$ )	Egg hatch inhibition ( $IC_{50}$ in $\mu M$ )	Cytotoxicity (48 h) $CC_{50}$ ( $\mu M$ )	Mitotoxicity (48 h) $MC_{50}$ ( $\mu M$ )
UMW-868		<i>n</i> -propyl	13.8	50.0	6.2	> 50.0	> 50.0
A-3126	Ph	—	12.1	50.0	13.1	> 50.0	> 50.0
A-3136	4-MePh	—	4.8	12.5	7.5	> 50.0	> 50.0
A-6501	4-CF <sub>3</sub> Ph	—	1.6	6.3	> 50.0	> 50.0	> 50.0
A-6318 <sup>a</sup>	4-OMePh	—	1.4	1.6	38.0	> 50.0	48.2
A-4347 <sup>a</sup>	—	H	> 50.0	> 50.0	> 50.0	> 50.0	> 50.0
A-3134	—	4-OEt	7.3	> 50.0	> 50.0	> 50.0	> 50.0
A-4340	—	4-OCHF <sub>2</sub>	4.0	25.0	> 50.0	> 50.0	> 50.0
A-6316 <sup>a</sup>	—	4-OCF <sub>3</sub>	9.8	> 50.0	> 50.0	> 50.0	> 50.0
Tioxazafen		—	> 50.0	> 50.0	> 50.0	> 50.0	> 50.0
A-6325	4-CF <sub>3</sub> Ph	4-OCHF <sub>2</sub>	1.4	3.1	> 50.0	> 50.0	36.3

<sup>a</sup>Compounds included to guide the structure activity relationship to reach A-6325 (Figure 5).

phenyl ring and a 4-difluoromethoxy group replacing the *n*-propyl substituent (i.e., A-6325), gave an  $IC_{50}$  value of 1.4  $\mu M$  for xL3 motility reduction (Table 1). These findings were in accord with trends seen in the Vina scores predicted from *in silico* docking (Supplementary Table S6).

### 3 Discussion

Here, in a high-throughput phenotypic screening assay, we identified a tioxazafen-related anthelmintic candidate (UMW-868) that has reproducible and quite potent nematocidal activity against *H. contortus* and at least three other nematode species. Using thermal proteome profiling (TPP), we discovered a novel protein target (designated HCO\_011565) in *H. contortus* that interacts with UMW-868; we inferred a statistically confident structure for HCO\_011565 using the most advanced structural prediction program available, AlphaFold2 (Jumper et al., 2021); and we revealed clear structural homology of HCO\_011565 with orthologs in other key nematode species, but no homology match to any vertebrate protein in public databases. These findings (proof-of-principle) indicate/suggest that the final workflow established here (Supplementary Figure S4)—which combines *in vitro* screening, potency assessment and TPP-guided protein target identification with *in silico* structural prediction and ligand

docking—might be a useful tool to support the discovery of novel anthelmintics and matching “orphan” target candidates for prioritisation and subsequent evaluation. This has major implications, given the widespread problem of anthelmintic resistance in nematodes of major agricultural and veterinary significance worldwide.

The discovery of a previously unknown, parasite-specific protein target candidate, HCO\_011565, which has structural homologs in a range of parasitic nematodes, but is absent from host animals, is particularly attractive. Given the consistent expression/transcription of HCO\_011565 in key developmental stages of *H. contortus* (Figure 4), and evidence of chemical knock-down and cell death in *H. contortus* caused by UMW-868 (Figures 1, 2; Table 1), we propose that HCO\_011565 is an essential molecule—a proposal that will require experimental validation in the laboratory. In our opinion, essential orphan proteins, such as this, which are encoded by single-copy genes, are of major interest, because there is no redundancy (i.e., no paralogs within a species) in the target. Unpublished investigations by our group have estimated that 10–30% of protein-encoding genes encoded in the genomes of *H. contortus* and related parasitic nematodes are currently unknown (and are, thus, assigned orphan status), and have no homologs in any other invertebrate or vertebrate species for which comprehensive genomic or transcriptomic data are

presently available in public databases. Although homology has usually been assessed based on primary nucleotide and/or protein sequence comparisons, we now advocate for a structure-based approach, whereby proteins predicted to be orphans are first modelled using the algorithms AlphaFold2 (Jumper et al., 2021) and/or RosETTA (Baek et al., 2021), and then directly compared with structures available in the Protein Data Bank (PDB) using the server Dali (Holm, 2020). Such an approach will lead to a better annotation of orphan proteins, improve comparative analyses, and guide the selection and prioritisation of parasite-specific targets that are absent from host animals and invertebrates in the environment, which is particularly important to consider, given the challenges/problems that may arise following the (commercial) release of a new parasiticide, such as adverse impacts due to toxicity on the environment and on critically important invertebrates, including honey bees, other pollinators and endangered species, and the consumers of food (Beynon, 2012a; Beynon, 2012b; EFSA (European Food Safety Authority), 2019; Rasmussen et al., 2021).

*In silico* investigation indicated that there are structural orthologs of HCO\_011565 in other nematodes known to be susceptible to UMW-868 *in vitro* and/or *in vivo* (Figure 4), but such orthologs do not exist in host animals. UMW-868 was inferred to dock specifically into its proposed binding pocket in HCO\_011565 (Figure 4C), and into other sites in HCO\_011565 orthologs of other nematodes (i.e. *He. polygyrus*, *A. ceylanicum*, *N. americanus*, *C. elegans* and *S. ratti*; Supplementary Table S6). The evidence from TPP does indicate that UMW-868 binds to HCO\_011565, but we do not exclude the possibility that there might be other targets. Thus, further work would be needed to address this latter issue, and also to validate the proposed binding site (pocket) for UMW-868 in HCO\_011565 and its orthologs in other nematodes. Although the structure of tioxazafen is similar to that of UMW-868, and appears to bind in the same pocket in HCO\_011565, it is predicted not to dock as well as UMW-868 does (Vina score: -6.2; Supplementary Table S6), which is consistent with the finding that tioxazafen does not significantly affect the motility, development or viability of *H. contortus* larvae *in vitro* (Table 1), contrasting information presented in an ICT patent (South and Wilson, 2016). While tioxazafen may interact with HCO\_011565 (Supplementary Figure S3), it is readily possible that it has no actual target in *H. contortus* larvae. Although other UMW-868 analogs (e.g., A-4347, A-3134, A-4340 and A-6316), particularly those with *n*-propyl substituents, were predicted to dock into, or interact with, the same pocket in protein HCO\_011565 (cf. Supplementary Figure S3), they were also inactive against one or more stages of *H. contortus*, suggesting that factors such as mode of uptake, absorption, transport, metabolism and/or biotransformation might explain this lack of activity. Overall, this work suggests that comparative docking might be a useful tool to support the initial selection of anthelmintic-target candidates, prior to future

docking by molecular dynamic simulation (MDS) (Śledź and Cafilisch, 2018) and crystal structure-based investigations. We now propose that mechanism of action studies of UMW-868 be undertaken in *H. contortus*, for which extensive resources and tools exist for functional and SAR investigations; future work is also needed to verify that HCO\_011565 orthologs in other nematodes are genuine targets.

Taken together, the results of this study show that the combined laboratory-computational workflow established here has considerable potential for the discovery of novel anthelmintic targets and parasiticides.

## 4 Materials and methods

### 4.1 Compound library

The HitFinder Collection comprises 14,400 (synthetic) small molecular compounds representing the drug-like diversity of the Maybridge Screening Collection (Thermo Fisher Scientific). These compounds were selected from the collection using a clustering algorithm employing standard Daylight Fingerprints (Daylight Software; [www.daylight.com](http://www.daylight.com)) with the Tanimoto similarity index (Tanimoto, 1958), clustering at 0.71 similarity. The physicochemical properties of compounds, including cLogP and molecular weight, were calculated and analysed using the DataWarrior software (Sander et al., 2015) (version 5.5.0). All compounds in the library fit the five Lipinski rules (Lipinski, 2000) for “drug-likeness,” have a purity of >90% and have been selected to be non-reactive, minimising false positive results and ensuring high-quality results. These compounds were supplied at a concentration of 10 mM in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich).

### 4.2 Production and storage of *H. contortus*

The Haecon-5 strain of *H. contortus* was maintained in experimental sheep as described previously (Schwarz et al., 2013; Preston et al., 2015), in accordance with the institutional animal ethics guidelines and the regulations of Australia (permit no. 1714374; University of Melbourne). In brief, helminth-free Merino sheep (6 months of age; male) were orally inoculated (*via* a gastric tube) with 7,000 L3s of *H. contortus*.

Four weeks after infection, faecal samples containing *H. contortus* eggs were collected daily from sheep with patent infection. *H. contortus* L3s were produced from eggs by incubating these faecal samples at 27°C and >90% relative humidity for 7 days (Preston et al., 2015), and collected in tap water and sieved through two layers of nylon mesh (pore size: 20 µm; Rowe Scientific) to remove debris or dead larvae, and then stored (at a concentration of 2,000 L3s per ml) at 11°C for up to

6 months (Preston et al., 2015). Immediately prior to use, L3s were exsheathed and sterilised by incubation in 0.15% (*v/v*) bleach at 38°C for 20 min<sup>20</sup>. Following this standard treatment, exsheathed L3s (xL3s) were immediately washed five times in 50 ml of sterile saline by centrifugation at 500 g (5 min) at room temperature (22°C–24°C). After the last wash, xL3s were suspended in sterile lysogeny broth (Bertani, 1951), supplemented with 100 IU/ml of penicillin, 100 µg/ml of streptomycin and 0.25 µg/ml of amphotericin B (Fungizone<sup>®</sup>, Thermo Fisher Scientific)—designated LB\*.

### 4.3 High throughput screening of compounds on *H. contortus*

An established platform was used for compound screening (Taki et al., 2021a). Using a semi-automated liquid handling robot (VIAFLO ASSIST PLUS, Integra Biosciences), compounds were individually diluted to 20 µM in LB\* containing 0.2% (*v/v*) DMSO and then dispensed in 20 µl into the wells of sterile 384-well flat bottom microtitre plates (cat. no. 3680; Corning); 320 compounds were arrayed on each plate, with 16 wells being negative controls (with LB\* + 0.2% DMSO) and four wells containing each monepantel (Zolvix; Elanco), moxidectin (Cydectin; Virbac), monepantel + abamectin (Zolvix Plus; Elanco) and compound MIPS-0018666 (abbreviated here as M-666) (Le et al., 2018) as positive controls (20 µM). Following the dilution and dispensing of compounds into plates, 80 *H. contortus* xL3s in 20 µl of LB\* were transferred to individual wells; after this step, the final concentrations were 20 µM of test- or positive-control compound, and 0.2% of DMSO. During dispensing, xL3s were maintained in a homogenous suspension using a constant stream of bubbles produced employing an aquarium pump (H2Pro). Plates containing *H. contortus* xL3s were incubated at 38 °C, 10% (*v/v*) CO<sub>2</sub> and >90% relative humidity.

After 90 h of incubation with compounds (20 µM), *H. contortus* xL3s motility was measured for 15 min in individual wells of each plate by infrared light beam-interference (Simonetta and Golombek, 2007) using a WMicroTracker ONE instrument (Phylumtech). Raw data captured were normalised against measurements obtained for the positive (monepantel) and negative (LB\* + 0.2% DMSO) controls to remove plate-to-plate variation by calculating the percentage of motility using the program GraphPad Prism (v.9.1.2; GraphPad Software). A compound was considered active (“hit”) if it reduced larval motility by ≥ 70%. To continually assess the performance of the screening assay, the *Z'*-factor (Zhang et al., 1999) was calculated (using data for the DMSO and the M-666 controls) for individual plates (*n* = 43) and was consistently ≥0.7; reliable assays achieve a *Z'*-factor of between 0.5 and 1. The signal to background (S/B) ratio (for the same controls) (Sui and Wu, 2007) was consistently >200.

Following the measurement of xL3 motility, plates were incubated again for 78 h (i.e., a total of 168 h) under the same conditions. Thereafter, 40 µl of 1% (*v/v*) iodine were added to individual wells, and worms examined using a light microscope (M80, Leica) at 60-times magnification to assess larval development, based on the presence/absence of a well-developed pharynx (Sommerville, 1966), and/or phenotypic alterations with respect to untreated xL3s.

### 4.4 Dose-response evaluations on *H. contortus*

These evaluations were carried out to estimate the half-maximal inhibitory concentrations (IC<sub>50</sub> values) for hit compounds against *H. contortus* xL3s. With reference to the two positive-control compounds (monepantel and moxidectin), IC<sub>50</sub> values for compounds were estimated (Preston et al., 2015; Taki et al., 2021a) using two-fold serial dilution (in LB\*; 9 points from 50 µM to 0.2 µM) in 96-well plates (cat. no. 3596; Corning) with larvae at a density of 300 *H. contortus* xL3s in 100 µl per well. Plates containing *H. contortus* xL3s were incubated at 38°C, 10% (*v/v*) CO<sub>2</sub> and >90% relative humidity.

The motility of *H. contortus* xL3s and L4 development were measured following 168 h of incubation with compound (Taki et al., 2021a). Compound concentrations were log<sub>10</sub>-transformed and fitted using a variable slope four-parameter equation, constraining the highest value to 100% employing a least squares (ordinary) fit model using GraphPad Prism software (v.9.1.2). Compounds were tested by three independent experiments in triplicate. A one-way analysis of variance (ANOVA) with a Tukey’s multiple comparison test or an unpaired *t*-test was used to establish statistically significant differences in larval motility or development.

### 4.5 Assessing compound activity against the adult and egg stages of *H. contortus*

Adult females of *H. contortus* collected from the abomasum of an infected sheep with patent infection (4 weeks) were used to assess the activity of compound UMW-868 in an established motility assay (Le et al., 2018). Each compound was added in triplicate to the wells of a 24-well plate (cat. no. 3524; Corning) at a concentration of 100 µM in 500 µl of phenol-red free Roswell Park Memorial Institute 1,640 medium (RPMI; Thermo Fisher Scientific) supplemented with 100 IU/ml of penicillin, 100 µg/ml of streptomycin and 0.25 µg/ml of amphotericin B (designated RPMI\*). Two positive-control compounds, monepantel and moxidectin, at 100 µM, and medium containing 0.2% (*v/v*) DMSO were included in the same plate in triplicate to serve as negative controls. Four adult females of *H. contortus* were assessed in each of the triplicate wells containing the test compound, and the positive and negative controls, and

incubated for 24 h at 38°C, 10% (*v/v*) CO<sub>2</sub> and >90% relative humidity. At 1, 2, 3, 5 and 24 h during the incubation, a video recording (30 s) of each well was taken to assess the reduction in worm motility, using scores of 3 (“good”), 2 (“low”), 1 (“very low”) or 0 (“no movement”) (Taki et al., 2020). For each test or control compound, the motility scores for each of the triplicate wells were calculated, normalised against the scores of the negative control (100% motility) and recorded as a percentage.

Compounds were also assessed for their effect on the hatching of eggs of *H. contortus* *in vitro*. To do this, eggs were isolated from the faeces from sheep with patent (30 day-) *H. contortus* infection by sucrose flotation (Mes et al., 2007). Eggs were suspended in H<sub>2</sub>O at a concentration of one egg per  $\mu$ l. The eggs were dispensed into wells (in triplicate; 100 eggs per well) and incubated with two-fold serial dilutions (9 points from 50  $\mu$ M to 0.2  $\mu$ M in H<sub>2</sub>O) of individual test or control compounds for 48 h at 27°C and >90% relative humidity; wells with no compound were also included. The numbers (percentages) of eggs from which first-stage larvae (L1s) hatched were counted using a light microscope (M80, Leica) at a 40-times magnification. With reference to positive-control compounds (i.e., monepantel and moxidectin), IC<sub>50</sub> values of compounds were calculated.

#### 4.6 Assessing cell lethality in *H. contortus*

Fluorescence staining was employed to assess the ability of UMW-868 to reduce the viability of *H. contortus*. The xL3s were dispensed in 96-well plates at a density of 300 xL3 per well, and incubated with compounds UMW-868 or A-3155, non-active analogs of UMW-868, at 50  $\mu$ M at 38°C, 10% (*v/v*) CO<sub>2</sub> and >90% relative humidity. After 90 h of incubation, *H. contortus* xL3s were stained with Sytox Green nucleic acid stain (Thermo Fisher Scientific) at the final concentration of 1  $\mu$ M in LB\* in the same 96-well plates and incubated for 1 h at 38°C and 10% (*v/v*) CO<sub>2</sub> with >90% relative humidity. Following the incubation, the viability of larvae was evaluated by measuring the relative fluorescent units (RFU) of xL3s using an Omega FLUOstar microplate reader (BMG Labtech), with excitation and emission wavelengths set at 485 nm and 520 nm, respectively. The 96-well plates containing the stained larvae were returned to the incubator for further 78 h; after a total of 168 h of compound exposure, the stained larvae were examined under an inverted fluorescence microscope (DM IL, Leica) equipped with a green fluorescent protein filter (470/500/525 nm; Leica), and imaged using Leica Application Suite software (Leica).

#### 4.7 Testing the cellular and mitochondrial toxicities of compounds in HepG2 cells

The toxicities of compounds on cell and mitochondria were assessed to estimate their half-maximal cytotoxic concentrations

(CC<sub>50</sub>) and half-maximal mitotoxic concentrations (MC<sub>50</sub>), respectively. HepG2 human hepatoma cells were seeded into wells of a 96-well plate at a density of  $5.5 \times 10^4$  cells per well in 80  $\mu$ l of Dulbecco's modified eagle medium (DMEM; with GlutaMax™ cat. no. 10566016 or 4 mM L-glutamine cat. no. 11966025; Thermo Fisher Scientific), supplemented with 25 mM D-glucose (cytotoxicity) or D-galactose (mitotoxicity), 10% (*v/v*) inactivated foetal bovine serum (iFBS), 100 IU/ml of penicillin, 100  $\mu$ g/ml of streptomycin and 0.25  $\mu$ g/ml of amphotericin B (designated DMEM\*). Cells were allowed to adhere for 16 h at 37°C and 5% (*v/v*) CO<sub>2</sub> at > 90% relative humidity, then, incubated for 48 h with individual, serially-diluted compounds (two-fold serial dilution in DMEM\*; seven points from 50  $\mu$ M to 1.56  $\mu$ M) in a final volume of 100  $\mu$ l. For the assessment of toxicity on mitochondria, cells were starved of serum (DMEM\* without iFBS) for 4 h prior to the 48 h-incubation with compounds (Swiss and Will, 2011; Kamalian et al., 2015). Two positive control compounds, doxorubicin (cytotoxic control) and M-666 (mitotoxic control) were each added to three individual wells in each 96-well plate at a single concentration of 10  $\mu$ M. DMEM\* + 0.25% (*v/v*) DMSO was added to 12 wells in each plate as negative controls. Monepantel and moxidectin were also serially diluted — prepared in the same manner as test compounds — and used as (“non-toxic”) reference compounds. After 48 h of incubation, cell viability was determined by the crystal violet staining method (Śliwka et al., 2016). The absorbance (595 nm) of treated cells was normalised with reference to the negative control (100% viability). To determine the CC<sub>50</sub> and MC<sub>50</sub> values, compound concentrations were log<sub>10</sub>-transformed, baseline-corrected using a respective positive control (doxorubicin or M-666) and fitted using a variable slope four-parameter equation with a least squares (ordinary) fit model using GraphPad Prism software (v.9.1.2). Compounds and controls were tested in triplicate.

#### 4.8 Procurement of nematodes other than *H. contortus*

*Ancylostoma ceylanicum* and *Necator americanus* (hookworms) were each routinely maintained in Syrian golden hamsters (three week-old males from Janvier Laboratories, Le Genest-Saint-Isle), *Heligmosomoides polygyrus* in NMRI mice (three week-old females from Charles River; Sulzfeld), *Trichuris muris* in C57BL/6NRj mice (three week-old females from Janvier Laboratories), and *Strongyloides ratti* in Wistar rats (three week-old males from Janvier Laboratories) (Buchter et al., 2021; Keiser and Häberli, 2021), in accordance with the institutional animal ethics guidelines and the regulations of Switzerland (permit no. 2070; Swiss Tropical and Public Health Institute).

Hamsters were orally infected with 140 L3s of *A. ceylanicum* or 150 L3 *N. americanus*, rats were subcutaneously injected with 1,300 L3s of *S. ratti*, and mice were orally inoculated with 88 L3s

of *He. polygyrus* or 200 embryonated *T. muris* eggs (Buchter et al., 2021; Keiser and Häberli, 2021). L3s of each *A. ceylanicum*, *N. americanus* and *He. polygyrus* were produced from eggs by incubating faeces from monospecifically infected animals for 8–10 days in the dark at 24°C and >90% humidity, and then isolated and concentrated using the Baermann technique (Garcia, 2001). *A. ceylanicum* and *N. americanus* L3s were suspended in Hanks' balanced salt solution (HBSS; Thermo Fisher Scientific), *He. polygyrus* L3s in RPMI 1640 medium and *S. ratti* L3s in phosphate-buffered saline (PBS, pH 7.4), with each medium containing 100 IU/ml of penicillin, 100 IU/ml of streptomycin and ~0.25 µg/ml of amphotericin B.

Adult *A. ceylanicum* and *S. ratti* were collected from the intestines of infected hamsters and rats after 3–6 weeks of infection. Adult *T. muris* were collected from the intestines of infected mice after 7 weeks of infection. *A. ceylanicum* were suspended in HBSS supplemented with 10% (v/v) inactivated foetal calf serum (Bioconcept AG, Allschwil), *S. ratti* RPMI 1640 medium supplemented with 5% (v/v) inactivated foetal calf serum and *T. muris* in RPMI 1640 medium plus 5% (v/v) inactivated foetal calf serum, with each medium containing penicillin/streptomycin and amphotericin B (same concentrations as for L3s), and incubated at 37°C in 5% (v/v) CO<sub>2</sub>.

#### 4.9 Assessing compound activity *in vitro* against other nematodes

For each *A. ceylanicum*, *He. polygyrus* and *S. ratti*, L3s were dispensed into 96-well plates at a density of 30–40 L3s per well, and exposed to 1 µM and/or 10 µM of each compound in a final volume of 250 µl. Each compound was tested in triplicate at each concentration. L3s in media containing 1% (v/v) DMSO served as a negative control. Plates were kept in the dark at 22°C, and those containing *N. americanus* was incubated at 37°C, 5% (v/v) CO<sub>2</sub> and >90% relative humidity. After 72 h of incubation with compounds, larval death was assessed by counting motile L3s following stimulation with 50–80 µl of hot water (~80°C).

For each *A. ceylanicum*, *S. ratti* and *T. muris*, adult worms (both sexes) were dispensed into wells of 24-well plates at a density of three (*A. ceylanicum* and *T. muris*) or six (*S. ratti*) worms per well, and exposed to 1 µM and 10 µM of compound or DMSO (same concentrations; negative control) in a final volume of 2.0 ml. For each concentration, compounds were tested in duplicate. *A. ceylanicum* and *S. ratti* were incubated at 22°C (in the dark), and *T. muris* at 37°C, 5% (v/v) CO<sub>2</sub> and >90% relative humidity. After a 72 h incubation, adult worms in individual wells were examined microscopically using a viability scale from 3 (“normal activity”) to 0 (“dead”), following stimulation with 500 µl of hot water (~80°C) (Keiser et al., 2016).

#### 4.10 Evaluating compound activity *in vivo* against other parasitic nematodes

Candidate compound(s) were tested for their effect on other nematode species (*He. polygyrus* and *A. ceylanicum*) in infected rodents.

For *He. polygyrus*, four NMRI mice (3 weeks old; female) were infected orally with 88 *He. polygyrus* L3s, and immunosuppressed with 0.25 mg/ml dexamethasone (Sigma-Aldrich), in the drinking water, until 2 days prior to treatment (Mes et al., 2007). For *A. ceylanicum*, four Syrian golden hamsters (3 weeks old; male) were infected orally with 300 L3s without immunosuppression (Tritten et al., 2012). Fourteen days or 23 days after the infection, mice and hamsters, respectively, were treated orally with UMW-868 at dosages of 100 mg/kg *bw* (mice and hamsters). Four each of untreated mice and hamsters served as placebo controls. Six to 7 days post-treatment with the compound, all animals were euthanised by CO<sub>2</sub> (hamsters being initially narcotised using isoflurane), and the intestine was dissected. The live adult worms were collected and counted to calculate the worm burden reductions and worm expulsion rates. The worm burden reduction was calculated using the mean number of live worms for the treated group and establishing the differences, in a percentage, with reference to the untreated control group.

#### 4.11 Thermal proteome profiling

TPP is an advanced, multiplexed mass-spectrometry method that allows the unbiased identification or detection of drug targets (Savitski et al., 2014; Perrin et al., 2020; Mateus et al., 2022); it relies on the thermostability of protein-drug interactions to identify potential target protein(s) through denaturation profiles (melting curves) upon heat treatment (Childs et al., 2019), and has proven capacity to specifically identify targets of anti-cancer drugs or drug candidates (Savitski et al., 2014; Perrin et al., 2020; Mateus et al., 2022). Here, we followed an established TPP protocol (Jafari et al., 2014), which has five steps (i.e., preparation of parasite protein extracts; incubation with compound and “heating” of samples; protein digestion and peptide labelling; mass spectrometric analysis; and data processing and analysis; cf. Figure 3):

- (i) Preparation of protein extracts from *H. contortus*: L3s of *H. contortus* were exsheathed using established methods (Taki et al., 2021a), collected by centrifugation (2,000 x g for 5 min) and frozen at –80°C following the removal of the supernatant. Subsequently, the frozen pellet (containing 30,000 xL3s) was ground to a fine powder in liquid nitrogen using a mortar and pestle, transferred to a 10 ml tube, suspended in 3 ml ice-cold phosphate-buffered saline (pH 7.0) containing 0.5% (v/v) nonyl

phenoxyethoxyethanol (NP-40), with or without protease inhibitors (cocktail set I; Merck, Denmark; TPP results achieved with inhibitors were the same as without), and lysed by gentle aspiration/expulsion using a 5 ml sterile syringe with a 22-gauge needle. Subsequently, the supernatant was collected from this suspension following centrifugation at 20,000  $\times$  g for 20 min at 4°C. The protein concentration in the supernatant was measured using a BCA Protein Assay Kit (Thermo Fisher Scientific), adjusted to 2 mg/ml and divided into four 250  $\mu$ l aliquots/replicates (each containing 500  $\mu$ g protein).

- (ii) Incubation with compound (UMW-868), and temperature profile: Of the four 250  $\mu$ l aliquots of xL3 proteins, two (i.e., test-samples) were each incubated with an equal volume of compound (UMW-868 at 50  $\mu$ M), and two (control-samples) with an equal volume of PBS (pH 7.0) for 30 min at 23°C. Each of the samples (containing 500  $\mu$ l) was partitioned into 10 PCR tubes (50  $\mu$ l each); individual pairs of test- and control-samples were simultaneously incubated in a thermal cycler (Applied Biosystems) at 10 distinct temperatures (37, 41, 44, 47, 50, 53, 56, 59, 63 and 67°C) for 3 min. Subsequently, all 40 tubes were centrifuged 20,000  $\times$  g for 20 min at 4°C, and soluble proteins (i.e., from above the pellet) collected into fresh tubes (each containing 45  $\mu$ l).
- (iii) In-solution digestion and isobaric stable isotope labelling of peptides: Proteins in aliquots (45  $\mu$ l) of individual samples ( $n = 40$ ) were denatured in 8 M urea for 30 min at 37°C and diluted to <2 M urea using lysis buffer prior to processing for in-solution digestion (Ang et al., 2011). Samples were reduced with 10 mM tris (2-carboxyethyl) phosphine (TCEP), alkylated with 55 mM iodoacetamide, followed by digestion with trypsin (Promega) at 37°C for 16 h. The trypsin-treated samples were acidified with 1.0% ( $v/v$ ) formic acid (FA) and purified using Oasis HLB cartridges (Waters; wash solvent, 0.1% FA; elution solvent, 80% acetonitrile (ACN) in 0.1% FA). Then, proteins were labelled with tandem mass tags (TMTs) (Zecha et al., 2019). In brief, desalted peptides were resuspended in 50 mM triethylammonium bicarbonate (TEAB) (pH 8.5) and mixed with a TMT10plex reagent (Thermo Fisher Scientific) that dissolved in 41  $\mu$ l anhydrous acetonitrile. The TMT-peptide mixture was incubated for 1 h at 25°C with gentle shaking. Sequentially, 3.2  $\mu$ l of 5% ( $w/v$ ) hydroxylamine was added to the mixture and incubated for 15 min at 25°C with gentle shaking to quench the reaction. Labelled peptides were combined accordingly and then desalted on Oasis HLB cartridges (Waters; using wash solvent, 0.1% FA; elution solvent, 80% acetonitrile (ACN) in 0.1% FA). Each mixed peptide sample was separated into eight fractions using the high pH reversed-phase peptide fractionation kit (Pierce), according to the manufacturer's protocol. All fractions

were freeze-dried prior to resuspension in aqueous 2% ( $w/v$ ) acetonitrile and 0.05% ( $w/v$ ) trifluoroacetic acid (TFA) before LC-MS/MS analysis.

- (iv) LC-MS/MS analysis, and protein identification/annotation: LC-MS/MS was performed on the Exploris 480 Orbitrap mass spectrometer (Thermo Fisher Scientific). The LC system was equipped with an Acclaim Pepmap nano-trap column (Dinoex-C18, 100  $\text{Å}$ , 75  $\mu$ m  $\times$  2 cm) and an Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100  $\text{Å}$ , 75  $\mu$ m–50 cm). The tryptic peptides were injected into the enrichment column at an isocratic flow of 5  $\mu$ l/min of 2% ( $v/v$ ) CH<sub>3</sub>CN containing 0.05% ( $v/v$ ) TFA for 6 min, applied before the enrichment column was switched in-line with the analytical column. The eluents were 0.1% ( $v/v$ ) FA (solvent A) in H<sub>2</sub>O and 100% ( $v/v$ ) CH<sub>3</sub>CN in 0.1% ( $v/v$ ) FA (solvent B), both supplemented with 5% DMSO. The gradient was at 300 nl/min from (i) 0–6 min, 3% B; (ii) 6–7 min, 3%–4% B; (iii) 7–82 min, 4%–25% B; (iv) 82–86 min, 25%–40% B; (v) 86–87 min, 40%–80% B; (vi) 87–90 min, 80–80 3% B; (vii) 90–90 min, 80%–3% B and equilibrated at 3% B for 10 min before injecting the next sample. The Exploris 480 Orbitrap mass spectrometer was operated in the data-dependent mode, whereby full MS1 spectra were acquired in a positive mode, with spray voltage at 1.9 kV, source temperature at 275°C, MS1 at 120,000 resolution, normalised AGC target of 300% and maximum IT time of 25 ms. The top 3 s method was used and selecting peptide ions with charge states of  $\geq 2$ –7 and intensity thresholds of  $\geq 5e^3$  were isolated for MS/MS. The isolation window was set at 0.7 m/z, and precursors were fragmented using higher energy C-trap dissociation (HCD) at a normalised collision energy of 35, a resolution of 30,000 (TurboTMT activated), a normalised AGC target of 200% and automated IT time.

Mass spectrometry data were processed using MaxQuant (Tyanova et al., 2016) for the identification and quantification of peptides/proteins. Proteins were matched to those inferred from the reference genome (version 4) for *H. contortus* (Doyle et al., 2020) and sequences in the NCBI non-redundant (nr) database (Pruitt et al., 2012). The MaxQuant default methods were used for reporter MS2 TMT based workflow. The TMT reagent was corrected for natural carbon isotopes and incomplete stable isotope incorporation. Fixed modifications of carbamidomethylation of cysteine. Trypsin/P was set as the protease with a maximum of two missed cleavages. Variable modifications are oxidation of methionine and acetylation of protein N-terminus. Protein and PSM false discovery rates (FDR) were both set at < 0.01. Results are available via the PRIDE data repository (accession number: PXD034868).

- (v) Data processing and analysis: The protein data produced by MaxQuant was taken for analysis in R (v.4.1.2). Decoy proteins, contaminant proteins, proteins only identified

by modified peptides, and proteins that were identified by less than two razor or unique peptides were removed. Corrected reporter ion intensities were then divided by the intensity of the 37°C channel. In two cases, where TMT reporter ion channels showed significantly lower intensity than expected, values were imputed by taking the average of the two adjacent channels. Due to the marked decrease in overall protein abundance with increasing temperature, protein abundance ratios were grouped by treatment temperature and subjected to quantile normalisation using the *limma* (v3.50.0) (Ritchie et al., 2015). Proteins were filtered to retain only those with non-zero values for each sample, and these were taken for subsequent analysis.

Thermal profiles of quantified proteins were assessed using the package NPARC (version 1.6.0) (Childs et al., 2019), which fits nonparametric models to the temperature profile data under null and alternative hypotheses; *p*-values were then calculated from *F*-statistics with empirically estimated degrees of freedom, as described in the NPARC package documentation (Perrin et al., 2020). Melting profiles were plotted and manually inspected for top ranking protein hits that were statistically significant (Benjamini-Hochberg-adjusted *p*-values were <0.05).

## 4.12 Protein structure prediction, and protein-ligand docking

The three-dimensional structures of proteins were predicted using the machine learning algorithm AlphaFold2 (Jumper et al., 2021), which is an advanced, artificial intelligence (AI) program—developed by DeepMind and acquired by Alphabet/Google; this program uses a neural network (deep-learning) (Jumper et al., 2021) to predict the three-dimensional structures of proteins from their primary amino acid sequences, and achieves high levels of accuracy/confidence compared with conventional, homology-based modelling methods. Here, to model interactions between *Haemonchus* protein and the compound (UMW-868), the docking server CB-Dock (<http://cao.labshare.cn/cb-dock/>) was used for automated cavity detection and evaluation (Liu et al., 2019) of selected proteins, followed by performing the protein-ligand docking using AutoDock Vina algorithm; resultant “Vina” scores reflected binding modes (Trott and Olson, 2010). Protein structures were displayed in ChimeraX (Pettersen et al., 2021).

## 4.13 Phylogenetic analysis

The amino acid sequences of orthologous proteins were aligned using MAFFT v7.490 employing the *linsi* option (Katoh and Standley, 2013). Gaps and poorly aligned regions of the alignment were removed using trimAl v1.4.

rev15 using the *-automated1* option (Capella-Gutierrez et al., 2009). The Akaike Information Criteria (AIC) test in ModelFinder (Kalyaanamoorthy et al., 2017) selected the LG model of evolution for subsequent phylogenetic analysis (Le and Gascuel, 2008). Bayesian phylogenetic inference (BI) was determined using Markov chain Monte Carlo (MCMC) analysis in MrBayes (Ronquist et al., 2012). One million generations of MCMC analysis were performed, and trees were recorded every 200th generation. At this point, the standard deviation of split frequencies was <0.01, and the potential scale reduction factor (PSRF) approached 1. Consensus trees (50% majority rule) were generated using the final 75% of trees. Trees were annotated and enhanced using the *ggtree* R package (v1.16.6) (Yu et al., 2017), and nodal support values on trees were indicated as posterior probabilities (pp).

## 4.14 Chemistry procedures

All non-aqueous reactions were performed under an atmosphere of nitrogen, unless otherwise specified. Commercially available reagents were used without further purification. Flash chromatography was performed with silica gel 60 (particle size 0.040–0.063 μm) on a CombiFlash Rf Purification System (Teledyne Isco) with mobile phase gradients as specified. NMR spectra were recorded on a Bruker Avance DRX 300 with the solvents indicated (<sup>1</sup>H NMR at 300 MHz). Chemical shifts are reported in ppm on the δ scale and referenced to the appropriate solvent peak. LCMS were analysed on an Agilent LCMS system equipped with an Agilent G6120B Mass Detector, 1,260 Infinity G1312B Binary pump, 1,260 Infinity G1367E HiPALS autosampler, and 1,260 Infinity G4212B Diode Array Detector. The LCMS conditions were as follows: column: Luna Omega (1.6 μm, C18, 50 × 2.1 mm); injection volume: 1 μl; gradient: 5–100% B over 3.8 min (solvent A: water/0.1% formic acid; solvent B: ACN/0.1% formic acid); acquisition time: 4.1 min; flow rate: 1 ml/min; detection: 254 and 214 nm. Unless otherwise noted, all compounds were found to be >95% pure by this method. The preparative LCMS purification were performed using a Waters preparative HPLC system equipped with Waters ZQ 3100 Mass Detector, Waters 2545-Pump, Waters SFO System Fluidics Organizer, Waters 2,996 Diode Array Detector and Waters 2,767 Sample Manager. The preparative-HPLC conditions were as follows: XBridge BEH C18 OBD Prep Column (130 Å, 5 μm, 19 mm × 100 mm); injection volume: 1 ml; gradient is variable over 20 min depending on each compound (solvent A: water/0.1% formic acid; solvent B: ACN/0.1% formic acid); flow rate, 20 ml/min; detection 100–600 nm. Chiral HPLC analysis was performed with the aforementioned Waters system using a Phenomenex Lux 5u Cellulose-3 (250 × 10 mm) column and a gradient of 45% ACN/55% water at 3 ml/min and 214 nm

detection. The specific procedures for the synthesis of analogs of the nematocidal compound—UMW-868—are given in [Supplementary File S1](#).

## Data availability statement

The datasets presented in this study has been deposited in the PRIDE repository with the accession number PXD034868.

## Ethics statement

The animal study was reviewed and approved by The University of Melbourne and Swiss Tropical and Public Health Institute.

## Author contributions

AT, TW, JB, NN, and C-SA conducted the laboratory work and/or developed methods. RG, AT, and TW wrote the manuscript with inputs from NY, BS, NN, GM, AH, JK, and AJ; BS and NN conducted chemistry; TW, C-SA, SN, AK, and NW conducted proteomics; ML undertook the thermal proteome data analyses; JK and CH conducted animal experiments; TW, NY, YZ, and PK undertook informatics and assisted in displaying results. AH assisted with structural modeling and interpretation of docking results; and RG and BC funded the project. All authors read, commented on and approved the submitted version of the manuscript.

## References

- Ang, C.-S., Binos, S., Knight, M. I., Moate, P. J., Cocks, B. G., and McDonagh, M. B. (2011). Global survey of the bovine salivary proteome: Integrating multidimensional prefractionation, targeted, and glyco-capture strategies. *J. Proteome Res.* 10, 5059–5069. doi:10.1021/pr200516d
- Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., et al. (2021). Accurate prediction of protein structures and interactions using a three-track neural network. *Science* 373, 871–876. doi:10.1126/science.abj8754
- Bertani, G. (1951). Studies on lysogenesis. I. The mode of phage liberation by lysogenic *Escherichia coli*. *J. Bacteriol.* 62, 293–300. doi:10.1128/JB.62.3.293-300.1951
- Beynon, S. A. (2012a). Potential environmental consequences of administration of anthelmintics to sheep. *Vet. Parasitol.* 189, 113–124. doi:10.1016/j.vetpar.2012.03.040
- Beynon, S. A. (2012b). Potential environmental consequences of administration of ectoparasiticides to sheep. *Vet. Parasitol.* 189, 125–135. doi:10.1016/j.vetpar.2012.03.041
- Buchter, V., Hofmann, D., Haberli, C., and Keiser, J. (2021). Characterization of moxidectin against *Strongyloides ratti*: *In vitro* and *in vivo* activity and pharmacokinetics in the rat model. *ACS Infect. Dis.* 7, 1069–1076. doi:10.1021/acscinfdis.0c00435
- Capella-Gutierrez, S., Silla-Martinez, J. M., and Gabaldon, T. (2009). trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25, 1972–1973. doi:10.1093/bioinformatics/btp348
- Charlier, J., RinaLdi, L., Musella, V., Ploeger, H. W., Chartier, C., Vineer, H. R., et al. (2020). Initial assessment of the economic burden of major parasitic helminth infections to the ruminant livestock industry in Europe. *Prev. Vet. Med.* 182, 105103. doi:10.1016/j.prevetmed.2020.105103
- Childs, D., Bach, K., Franken, H., Anders, S., Kurzawa, N., Bantscheff, M., et al. (2019). Nonparametric analysis of thermal proteome profiles reveals novel drug-binding proteins. *Mol. Cell. Proteomics* 18, 2506–2515. doi:10.1074/mcp.TIR119.001481
- Clare, R. H., Bardelle, C., Harper, P., Hong, W. D., Borjesson, U., Johnston, K. L., et al. (2019). Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. *Nat. Commun.* 10, 11. doi:10.1038/s41467-018-07826-2
- Davis, P., Zarowiecki, M., Arnaboldi, V., Becerra, A., Cain, S., Chan, J., et al. (2022). WormBase in 2022 – data, processes, and tools for analyzing *Caenorhabditis elegans*. *Genetics* 220, iyac003. doi:10.1093/genetics/iyac003
- Doyle, S. R., Tracey, A., Laing, R., Holroyd, N., Bartley, D., Bazant, W., et al. (2020). Genomic and transcriptomic variation defines the chromosome-scale assembly of *Haemonchus contortus*, a model gastrointestinal worm. *Commun. Biol.* 3, 656. doi:10.1038/s42003-020-01377-3
- EFSA (European Food Safety Authority) (2019). Scientific support for preparing an EU position in the 51st session of the codex committee on pesticide residues (CCPR). *E.F.S.A. J.* 17, e05797. doi:10.2903/j.efsa.2019.5797
- Garcia, L. S. (2001). *Diagnostic medical Parasitology*. Washington D.C: ASM Press. 9781555812003.
- Gasser, R. B., Schwarz, E. M., Korhonen, P. K., and Young, N. D. (2016). Understanding *Haemonchus contortus* better through genomics and transcriptomics. *Adv. Parasitol.* 93, 519–567. doi:10.1016/bs.apar.2016.02.015
- Gordon, C. A., McManus, D. P., Jones, M. K., Gray, D. J., and Gobert, G. N. (2016). The increase of exotic zoonotic helminth infections the impact of urbanization, climate change and globalization. *Adv. Parasitol.* 91, 311–397. doi:10.1016/bs.apar.2015.12.002

## Funding

This work was supported by grants from the Australian Research Council (ARC), namely LP180101085, LP190101209, and LP180101334, and industry partners including Yourgene Health Singapore and PhylumTech (Argentina).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2022.1014804/full#supplementary-material>

- Hahnel, S. R., Dilks, C. M., Heisler, I., Andersen, E. C., and Kulke, D. (2020). *Caenorhabditis elegans* in anthelmintic research – old model, new perspectives. *Int. J. Parasitol. Drugs Drug Resist.* 14, 237–248. doi:10.1016/j.ijpddr.2020.09.005
- Harris, T. W., Arnaboldi, V., Cain, S., Chan, J., Chen, W. J., Cho, J., et al. (2019). WormBase: A modern model organism information resource. *Nucleic Acids Res.* 48, D762–D767. doi:10.1093/nar/gkz920
- HELP (Helminth Elimination Platform) (2019). *Public-private partnership launched to develop new drugs for roundworm infections*. Geneva, Switzerland. released on 28 November Available at: <https://dndi.org/press-releases/2019/public-private-partnership-launched-develop-ew-drugs-for-roundworm-infections/>.
- Herath, H. M. P. D., Taki, A. C., Rostami, A., Jabbar, A., Keiser, J., Geary, T. G., et al. (2022). Whole-organism phenotypic screening methods used in early-phase anthelmintic drug discovery. *Biotechnol. Adv.* 57, 107937. doi:10.1016/j.biotechadv.2022.107937
- Herath, H. M. P. D., Taki, A. C., Sleeb, B. E., Hofmann, A., Nguyen, N., Preston, S., et al. (2021). Advances in the discovery and development of anthelmintics by harnessing natural product scaffolds. *Adv. Parasitol.* 111, 203–251. doi:10.1016/bs.apar.2020.10.002
- Hodgkinson, J. E., Kaplan, R. M., Kenyon, F., Morgan, E. R., Park, A. W., Paterson, S., et al. (2019). Refugia and anthelmintic resistance: Concepts and challenges. *Int. J. Parasitol. Drugs Drug Resist.* 10, 51–57. doi:10.1016/j.ijpddr.2019.05.001
- Holden-Dye, L., and Walker, R. J. (2014). “Anthelmintic drugs and nematocides: Studies in *Caenorhabditis elegans*,” in *WormBook – online review of C. elegans Biology* (Pasadena, California, USA: The C. elegans Research Community), 1–29.
- Holm, L. (2020). Using Dali for protein structure comparison. *Methods Mol. Biol.* 2112, 29–42. doi:10.1007/978-1-0716-0270-6\_3
- Jafari, R., Almqvist, H., Axelsson, H., Ignatshchenko, M., Lundback, T., Nordlund, P., et al. (2014). The cellular thermal shift assay for evaluating drug target interactions in cells. *Nat. Protoc.* 9, 2100–2122. doi:10.1038/nprot.2014.138
- Jex, A. R., Lim, Y. A., Bethony, J. M., Hotez, P. J., Young, N. D., and Gasser, R. B. (2011). Soil-transmitted helminths of humans in Southeast Asia – towards integrated control. *Adv. Parasitol.* 74, 231–265. doi:10.1016/B978-0-12-385897-9.00004-5
- Jiao, Y., Preston, S., Hofmann, A., Taki, A., Baell, J., Chang, B. C. H., et al. (2020). A perspective on the discovery of selected compounds with anthelmintic activity against the barber’s pole worm—Where to from here? *Adv. Parasitol.* 108, 1–45. doi:10.1016/bs.apar.2019.12.003
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589. doi:10.1038/s41586-021-03819-2
- Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A., and Jermini, L. S. (2017). ModelFinder: Fast model selection for accurate phylogenetic estimates. *Nat. Methods* 14, 587–589. doi:10.1038/nmeth.4285
- Kamalian, L., Chadwick, A. E., Bayliss, M., French, N. S., Monshouer, M., Snoeys, J., et al. (2015). The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. *Toxicol. Vitro* 29, 732–740. doi:10.1016/j.tiv.2015.02.011
- Katoh, K., and Standley, D. M. (2013). MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol. Biol. Evol.* 30, 772–780. doi:10.1093/molbev/mst010
- Keiser, J., and Häberli, C. (2021). Evaluation of commercially available anthelmintics in laboratory models of human intestinal nematode infections. *ACS Infect. Dis.* 7, 1177–1185. doi:10.1021/acscinfecdis.0c00719
- Keiser, J., Panic, G., Adelfio, R., Cowan, N., Vargas, M., and Scandale, I. (2016). Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections. *Parasit. Vectors* 9, 376. doi:10.1186/s13071-016-1616-0
- Keiser, J., and Utzinger, J. (2008). Efficacy of current drugs against soil-transmitted helminth infections: Systematic review and meta-analysis. *J. A. M. A.* 299, 1937–1948. doi:10.1001/jama.299.16.1937
- Kotze, A. C., and Prichard, R. K. (2016). Anthelmintic resistance in *Haemonchus contortus*: History, mechanisms and diagnosis. *Adv. Parasitol.* 93, 397–428. doi:10.1016/bs.apar.2016.02.012
- Laing, R., Kikuchi, T., Martinelli, A., Tsai, I. J., Beech, R. N., Redman, E., et al. (2013). The genome and transcriptome of *Haemonchus contortus*, a key model parasite for drug and vaccine discovery. *Genome Biol.* 14, R88. doi:10.1186/gb-2013-14-8-r88
- Le, S. Q., and Gascuel, O. (2008). An improved general amino acid replacement matrix. *Mol. Biol. Evol.* 25, 1307–1320. doi:10.1093/molbev/msn067
- Le, T. G., Kundu, A., Ghoshal, A., Nguyen, N. H., Preston, S., Jiao, Y., et al. (2018). Optimization of novel 1-methyl-1 h -pyrazole-5-carboxamides leads to high potency larval development inhibitors of the barber’s pole worm. *J. Med. Chem.* 61, 10875–10894. doi:10.1021/acs.jmedchem.8b01544
- Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. *J. Pharmacol. Toxicol. Methods* 44, 235–249. doi:10.1016/s1056-8719(00)00107-6
- Liu, Y., Grimm, M., Dai, W. T., Hou, M. C., Xiao, Z. X., and Cao, Y. (2019). CB-dock: A web server for cavity detection-guided protein-ligand blind docking. *Acta Pharmacol. Sin.* 41, 138–144. doi:10.1038/s41401-019-0228-6
- Loukas, A., Maizels, R. M., and Hotez, P. J. (2021). The yin and yang of human soil-transmitted helminth infections. *Int. J. Parasitol.* 51, 1243–1253. doi:10.1016/j.ijpara.2021.11.001
- Ma, G., Gasser, R. B., Wang, T., Korhonen, P. K., and Young, N. D. (2020). Toward integrative ‘omics of the barber’s pole worm and related parasitic nematodes. *Infect. Genet. Evol.* 85, 104500. doi:10.1016/j.meegid.2020.104500
- Ma, G., Wang, T., Korhonen, P. K., Ang, C. S., Williamson, N. A., Young, N. D., et al. (2018). Molecular alterations during larval development of *Haemonchus contortus* in vitro are under tight post-transcriptional control. *Int. J. Parasitol.* 48, 763–772. doi:10.1016/j.ijpara.2018.03.008
- Ma, G., Wang, T., Korhonen, P. K., Hofmann, A., Sternberg, P. W., Young, N. D., et al. (2020). Elucidating the molecular and developmental biology of parasitic nematodes: Moving to a multiomics paradigm. *Adv. Parasitol.* 108, 175–229. doi:10.1016/bs.apar.2019.12.005
- Mateus, A., Kurzawa, N., Perrin, J., Bergamini, G., and Savitski, M. M. (2022). Drug target identification in tissues by thermal proteome profiling. *Annu. Rev. Pharmacol. Toxicol.* 62, 465–482. doi:10.1146/annurev-pharmtox-052120-013205
- McCarthy, J., and Moore, T. A. (2000). Emerging helminth zoonoses. *Int. J. Parasitol.* 30, 1351–1360. doi:10.1016/s0020-7519(00)00122-3
- Mes, T. H., Eysker, M., and Ploeger, H. W. (2007). A simple, robust and semi-automated parasite egg isolation protocol. *Nat. Protoc.* 2, 486–489. doi:10.1038/nprot.2007.56
- Partridge, F. A., Brown, A. E., Buckingham, S. D., Willis, N. J., Wynne, G. M., Forman, R., et al. (2018). An automated high-throughput system for phenotypic screening of chemical libraries on *C. elegans* and parasitic nematodes. *Int. J. Parasitol. Drugs Drug Resist.* 8, 8–21. doi:10.1016/j.ijpddr.2017.11.004
- Pasche, V., Laleu, B., and Keiser, J. (2018). Early antischistosomal leads identified from *in vitro* and *in vivo* screening of the medicines for malaria venture pathogen box. *ACS Infect. Dis.* 5, 102–110. doi:10.1021/acscinfecdis.8b00220
- Pedersen, A. B., and Fenton, A. (2015). The role of antiparasite treatment experiments in assessing the impact of parasites on wildlife. *Trends Parasitol.* 31, 200–211. doi:10.1016/j.pt.2015.02.004
- Perrin, J., Werner, T., Kurzawa, N., Rutkowska, A., Childs, D. D., Kalxdorf, M., et al. (2020). Identifying drug targets in tissues and whole blood with thermal-shift profiling. *Nat. Biotechnol.* 38, 303–308. doi:10.1038/s41587-019-0388-4
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Meng, E. C., Couch, G. S., Croll, T. I., et al. (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci.* 30, 70–82. doi:10.1002/pro.3943
- Preston, S., Jabbar, A., Nowell, C., Joachim, A., Ruttkowski, B., Baell, J., et al. (2015). Low cost whole-organism screening of compounds for anthelmintic activity. *Int. J. Parasitol.* 45, 333–343. doi:10.1016/j.ijpara.2015.01.007
- Prichard, R. K. (2005). Is anthelmintic resistance a concern for heartworm control? What can we learn from the human filariasis control programs? *Vet. Parasitol.* 133, 243–253. doi:10.1016/j.vetpar.2005.04.008
- Pruitt, K. D., Tatusova, T., Brown, G. R., and Maglott, D. R. (2012). NCBI reference sequences (RefSeq): Current status, new features and genome annotation policy. *Nucleic Acids Res.* 40, D130–D135. doi:10.1093/nar/gkr1079
- Ramamoorthi, R., Graef, K. M., and Dent, J. (2014). WIPO Re:Search: Accelerating anthelmintic development through cross-sector partnerships. *Int. J. Parasitol. Drugs Drug Resist.* 4, 220–225. doi:10.1016/j.ijpddr.2014.09.002
- Rasmussen, A. S. B., Hammou, A., Poulsen, T. F., Laursen, M. C., and Hansen, S. F. (2021). Definition, categorization, and environmental risk assessment of biopharmaceuticals. *Sci. Total Environ.* 789, 147884. doi:10.1016/j.scitotenv.2021.147884
- Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., et al. (2015). Limma powers differential expression analyses for RNA-seq and microarray studies. *Nucleic Acids Res.* 43, e47. doi:10.1093/nar/gkv007
- Ronquist, F., Teslenko, M., van der Mark, P., Ayres, D. L., Darling, A., Höhna, S., et al. (2012). MrBayes 3.2: Efficient bayesian phylogenetic inference and model choice across a large model space. *Syst. Biol.* 61, 539–542. doi:10.1093/sysbio/sys029

- Sander, T., Freyss, J., von Korff, M., and Rufener, C. (2015). DataWarrior: An open-source program for chemistry aware data visualization and analysis. *J. Chem. Inf. Model.* 55, 460–473. doi:10.1021/ci500588j
- Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Eberhard, D., Savitski, M. F., et al. (2014). Tracking cancer drugs in living cells by thermal profiling of the proteome. *Science* 346, 1255784. doi:10.1126/science.1255784
- Schwarz, E. M., Korhonen, P. K., Campbell, B. E., Young, N. D., Jex, A. R., Jabbar, A., et al. (2013). The genome and developmental transcriptome of the stronglyid nematode *Haemonchus contortus*. *Genome Biol.* 14, R89. doi:10.1186/gb-2013-14-8-r89
- Selzer, P. M., and Epe, C. (2020). Antiparasitics in animal health: Quo vadis? *Trends Parasitol.* 37, 77–89. doi:10.1016/j.pt.2020.09.004
- Shanley, H. T., Taki, A. C., Byrne, J. J., Jabbar, A., Wells, T. N. C., Samby, K., et al. (2022). A high-throughput phenotypic screen of the 'Pandemic Response Box' identifies a quinoline derivative with significant anthelmintic activity. *Pharmaceuticals* 15, 257. doi:10.3390/ph15020257
- Simonetta, S. H., and Golombek, D. A. (2007). An automated tracking system for *Caenorhabditis elegans* locomotor behavior and circadian studies application. *J. Neurosci. Methods* 161, 273–280. doi:10.1016/j.jneumeth.2006.11.015
- Śledź, P., and Cafilisch, A. (2018). Protein structure-based drug design: From docking to molecular dynamics. *Curr. Opin. Struct. Biol.* 48, 93–102. doi:10.1016/j.sbi.2017.10.010
- Śliwka, L., Wiktorska, K., Suchocki, P., Milczarek, M., Mielczarek, S., Lubelska, K., et al. (2016). The comparison of MTT and CVS assays for the assessment of anticancer agent interactions. *PLoS One* 11, e0155772. doi:10.1371/journal.pone.0155772
- Sommerville, R. I. (1966). The development of *Haemonchus contortus* to the fourth stage *in vitro*. *J. Parasitol.* 52, 127–136. doi:10.2307/3276403
- South, M. S., and Wilson, D. (2016). *Compositions and methods for improving agronomic characteristics of plants*. Patent WO/2016/100766.
- Sui, Y., and Wu, Z. (2007). Alternative statistical parameter for high-throughput screening assay quality assessment. *J. Biomol. Screen.* 12, 229–234. doi:10.1177/1087057106296498
- Swiss, R., and Will, Y. (2011). Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactose-containing media. *Curr. Protoc. Toxicol.* 2, Unit2.20. Chapter 2, Unit 2.20. doi:10.1002/0471140856.tx0220s49
- Taki, A. C., Brkljaca, R., Wang, T., Koehler, A. V., Ma, G., Danne, J., et al. (2020). Natural compounds from the marine Brown alga *Caulocystis cephalornithos* with potent *in vitro*-activity against the parasitic nematode *Haemonchus contortus*. *Pathogens* 9, 550. doi:10.3390/pathogens9070550
- Taki, A. C., Byrne, J. J., Wang, T., Sleeb, B. E., Nguyen, N., Hall, R. S., et al. (2021). High-throughput phenotypic assay to screen for anthelmintic activity on *Haemonchus contortus*. *Pharmaceuticals* 14, 616. doi:10.3390/ph14070616
- Taki, A. C., Jabbar, A., Kurz, T., Lungerich, B., Ma, G., Byrne, J. J., et al. (2021). Three small molecule entities (MPK18, MPK334 and YAK308) with activity against *Haemonchus contortus* *in vitro*. *Molecules* 26, 2819. doi:10.3390/molecules26092819
- Tanimoto, T. T. (1958). *An elementary mathematical theory of classification and prediction*. New York, New York: International Business Machines Corporation.
- Taylor, M. J., von Geldern, T. W., Ford, L., Hubner, M. P., Marsh, K., Johnston, K. L., et al. (2019). Preclinical development of an oral anti-*Wolbachia* macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. *Sci. Transl. Med.* 11, eaa2086. doi:10.1126/scitranslmed.aau2086
- Tritten, L., Nwosu, U., Vargas, M., and Keiser, J. (2012). *In vitro* and *in vivo* efficacy of tribendimidine and its metabolites alone and in combination against the hookworms *Heligmosomoides bakeri* and *Ancylostoma ceylanicum*. *Acta Trop.* 122, 101–107. doi:10.1016/j.actatropica.2011.12.008
- Trott, O., and Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 31, 455–461. doi:10.1002/jcc.21334
- Tyanova, S., Temu, T., and Cox, J. (2016). The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* 11, 2301–2319. doi:10.1038/nprot.2016.136
- Vercruysse, J., Albonico, M., Behnke, J. M., Kotze, A. C., Prichard, R. K., McCarthy, J. S., et al. (2011). Is anthelmintic resistance a concern for the control of human soil-transmitted helminths? *Int. J. Parasitol. Drugs Drug Resist.* 1, 14–27. doi:10.1016/j.ijpdr.2011.09.002
- Wang, T., and Gasser, R. B. (2021). Prospects of using high-throughput proteomics to underpin the discovery of animal host–nematode interactions. *Pathogens* 10, 825. doi:10.3390/pathogens10070825
- Wang, T., Ma, G., Ang, C. S., Korhonen, P. K., Koehler, A. V., Young, N. D., et al. (2019). High throughput LC-MS/MS-based proteomic analysis of excretory-secretory products from short-term *in vitro* culture of *Haemonchus contortus*. *J. Proteomics* 204, 103375. doi:10.1016/j.jprot.2019.05.003
- Wang, T., Ma, G., Ang, C. S., Korhonen, P. K., Stroehlein, A. J., Young, N. D., et al. (2020). The developmental phosphoproteome of *Haemonchus contortus*. *J. Proteomics* 213, 103615. doi:10.1016/j.jprot.2019.103615
- Wang, T., Ma, G., Ang, C. S., Korhonen, P. K., Xu, R., Nie, S., et al. (2019). Somatic proteome of *Haemonchus contortus*. *Int. J. Parasitol.* 49, 311–320. doi:10.1016/j.ijpara.2018.12.003
- Wang, T., Ma, G., Nie, S., Williamson, N. A., Reid, G. E., and Gasser, R. B. (2020). Lipid composition and abundance in the reproductive and alimentary tracts of female *Haemonchus contortus*. *Parasit. Vectors* 13, 338. doi:10.1186/s13071-020-04208-w
- Wang, T., Nie, S., Ma, G., Korhonen, P. K., Koehler, A. V., Ang, C. S., et al. (2018). The developmental lipidome of *Haemonchus contortus*. *Int. J. Parasitol.* 48, 887–895. doi:10.1016/j.ijpara.2018.06.002
- Wang, T., Nie, S., Reid, G. E., and Gasser, R. B. (2021). Helminth lipidomics – technical aspects and future prospects. *Curr. Res. Parasitol. Vector. Borne. Dis.* 1, 100018. doi:10.1016/j.crpvbd.2021.100018
- Weber, C. J., Hargan-Calvoña, J., Graef, K. M., Manner, C. K., and Dent, J. (2019). WIPO Research – A platform for product-centered cross-sector partnerships for the elimination of schistosomiasis. *Trop. Med. Infect. Dis.* 4, 11. doi:10.3390/tropicalmed4010011
- Yu, G. C., Smith, D. K., Zhu, H. C., Guan, Y., and Lam, T. T. Y. (2017). GGTREE: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol. Evol.* 8, 28–36. doi:10.1111/2041-210x.12628
- Zecha, J., Satpathy, S., Kanashova, T., Avanesian, S. C., Kane, M. H., Clauser, K. R., et al. (2019). TMT labeling for the masses: A robust and cost-efficient, in-solution labeling approach. *Mol. Cell. Proteomics* 18, 1468–1478. doi:10.1074/mcp.TIR119.001385
- Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen.* 4, 67–73. doi:10.1177/108705719900400206